


Regeneration in Nature

- Outstanding Examples
 - Planarian
 - Crayfish
 - Embryos
- Inverse Relationship
 - Increase complexity
 - Decrease regenerative ability



Regeneration in Humans

High



Moderate




Low




Clinical Needs

- Cardiovascular
 - Myocardial infarction
 - Stroke
- Bone
 - Non-union fractures
 - Tumor resections
- Nervous
 - Spinal Cord Injury
 - Degenerative diseases





Stem Cells

- Long-term self-renewal
- Clonogenic
- Environment-dependent differentiation




Tissue Engineering

- Repair/replace damaged tissues
 - Enhance natural regeneration



Important Variables



Stem and Progenitor Cells

- Isolation/Identification
 - Signature of cell surface markers
 - Surface adherence
 - Transcription factors
- Classifications
 - Embryonic Stem Cells
 - Adult Stem Cells
 - Induced Pluripotent Stem Cells


Embryonic Stem Cells

Strengths

- Highest level of pluripotency
 - All somatic cell types
- Unlimited self-renewal
 - Enhanced telomerase activity
- Markers
 - Oct-4, Nanog, SSEA-3/4

Limitations

- Teratoma Formation
- Animal pathogens
- Immune Response
- Ethics



Potential Solutions

- Teratoma Formation
 - Pre-differentiate cells in culture then insert
- Animal pathogens
 - Feeder-free culture conditions (Matrigel)
- Immune Response
 - Somatic cell nuclear transfer
 - Universalize DNA
- Ethics

Human Embryonic Stem Cell Lines Generated without Embryo Destruction

Young Chung,^{1,6} Irina Klimanskaya,^{1,6} Sandy Becker,¹ Tong Li,¹ Marc Maserati,¹ Shi-Jiang Lu,¹ Tamara Zdravkovic,² Dusko Ilic,³ Olga Genbacev,² Susan Fisher,^{2,4} Ana Krtolica,³ and Robert Lanza^{1,5,*}

Adult Stem Cells

Strengths

- Ethics, not controversial
- Immune-privileged
 - Allogenic, xenogenic transplantation
- Many sources
 - Most somatic tissues



Limitations

- Differentiation Capacity?
- Self-renewal?
- Rarity among somatic cells




Potential Solutions

- Differentiation Capacity
 - Mimic stem cell niche
- Limited Self-renewal
 - Gene therapy
- Limited availability
 - Fluorescence-activated cell sorting
 - Adherence
 - Heterogenous population works better clinically




Mesenchymal Stem Cells

- Easy isolation, high expansion, reproducible



Hematopoietic Stem Cells

- Best-studied, used clinically for 30+ years



Induced Pluripotent Stem Cells

Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors

Strengths


- Patient DNA match
- Similar to embryonic stem cells?

Limitations

- Same genetic pre-dispositions
- Viral gene delivery mechanism


Kazutoshi Takahashi,¹ Koji Tanabe,¹ Mari Ohnuki,¹ Megumi Narta,^{1,2} Tomoko Ichisaka,^{1,2} Kichiro Tomoda,³ and Shinya Yamanaka^{1,2,3,4,*}

Cell 131, 1–12, November 30, 2007



iPS cells
(Induced pluripotent stem cell)

iPS



fibroblast



ES



Potential Solutions

- Same genetic pre-dispositions
 - Gene therapy in culture
- Viral gene delivery mechanism
 - Polymer, liposome, controlled-release
- Use of known onco-genes
 - Try other combinations

Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease

Marius Wernig*, Jian-Ping Zhao[†], Jan Pruszak[‡], Eva Hedlund[‡], Dongdong Fu*, Frank Soldner*, Vania Broccoli[§], Martha Constantine-Paton[‡], Ole Isacson[‡], and Rudolf Jaenisch*^{¶||}

Soluble Chemical Factors

- Transduce signals
 - Cell type-dependent
 - Differentiation stage-dependent
 - Timing is critical
 - Dose-dependence




- Growth
- Survival
- Motility
- Differentiation

Factor	Cell or Tissue of Origin	Selected Target Cells or Tissue
EGF	macrophages, monocytes	epithelium, endothelial cells
FGF	monocytes, macrophages, endothelial cells	endothelium, fibroblasts, keratinocytes
GM-CSF	macrophages, fibroblasts, endothelial cells	hematopoietic, inflammatory cells, neutrophils, fibroblasts
HGH	pituitary gland	hepatocytes, bone, fibroblasts
IL-1	lymphocytes, macrophages, keratinocytes	monocytes, neutrophils, fibroblasts, keratinocytes
PDGF	platelets, macrophages, neutrophils, smooth muscle cells	fibroblasts, smooth muscle cells
TCF-β	platelets, bone, most cell types	fibroblasts, endothelial cells, keratinocytes, lymphocytes, monocytes

Scaffold purpose

- Temporary structural support —————> Structural
 - Maintain shape
- Cellular microenvironment —————> Surface coating
 - High surface area/volume
 - ECM secretion
 - Integrin expression
 - Facilitate cell migration



Ideal Extracellular Matrix

- 3-dimensional
- Cross-linked
- Porous
- Biodegradable
- Proper surface chemistry
- Matching mechanical strength
- Biocompatible
- Promotes natural healing
- Accessibility
- Commercial Feasibility



Modulate Properties
Physical, Chemical
Customize scaffold



Appropriate Trade-offs
Tissue
Disease condition

“Natural” Materials

- Polymers

- Collagen
- Laminin
- Fibrin
- Matrigel
- Decellularized matrix


- Ceramics

- Hydroxyapatite
- Calcium phosphate
- Bioglass

Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart.

Ott, et al.

Nat Med. 2008 Feb;14(2):213



Important scaffold variables


- Surface chemistry
- Matrix topography
 - Cell organization, alignment
 - Fiber alignment -> tissue development
- Rigidity
 - 5-23 kPa
- Porosity
 - Large interconnected
 - small disconnected

Mechanical Forces

- Flow-induced shear stress
 - Laminar blood flow
 - Rhythmic pulses
- Uniaxial, Equiaxial stretch
 - Magnitude
 - Frequency



Mechanotransduction

Conversion of a mechanical stimulus into a biochemical response



Flow-induced shear stress

- 2D parallel plate flow chamber
 - Hemodynamic force
 - Laminar flow
 - Pulsatile component
- 3D matrix
 - Interstitial flow
 - Bone: oscillating
- Cell-type specific



Models for Tissue Engineering

- *In vitro* differentiation
 - Construct tissues outside body before transplantation
 - Ultimate goal
 - Most economical
 - Least waiting time
- *In situ* methodology
 - Host remodeling of environment
- *Ex vivo* approach
 - Excision and remodeling in culture

Combine physical
and chemical factors



Optimize stem cell
differentiation and
organization

Delivery Methods

- Injectable stem cells
 - Cells or cell-polymer mix
 - Less invasive
 - Adopt shape of environment
 - Controlled growth factor release
- Solid scaffold manufacturing
 - Computer-aided design
 - Match defect shape





Cardiovascular Tissue Engineering


- Heals poorly after damage (non-functional scar tissue)
 - Myocardial infarction
 - 60% survival rate after 2 years
 - >40% tissue death requires transplantation
 - More patients than organ donors
- Heart attack and strokes
 - First and third leading causes of death
 - Patient often otherwise healthy

Current interventions

- Balloon angioplasty
 - Expanded at plaque site, contents collected
- Vascular stent
 - Deploy to maintain opening
- Saphenous vein graft
 - Gold Standard
 - Form new conduit, bypass blockage
- All interventions ultimately fail
 - 10 years maximum lifetime



Cardiovascular Tissue Engineering



Clinical Questions

- What cell source do you use?
- How should cells be delivered?
- What cells within that pool are beneficial?
- How many cells do you need?
- When should you deliver the cells?
- What type of scaffold should be used?

These answers all depend on each other

Very sensitive to methodology!

- 2 nearly identical clinical trials, opposite results
 - Autologous Stem cell Transplantation in Acute Myocardial Infarction (ASTAMI)
 - Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI)
- Same inclusion criteria
- Same cell source (Bone marrow aspirates)
- Same delivery mechanism (intracoronary infusion)
- Same timing of delivery
- **SIMILAR** cell preparation methods

Cell preparation comparison

- Bone marrow aspirates diluted with 0.9% NaCl (1:5)
- Mononuclear cells isolated on **Lymphoprep™** gradient 800rcf 20 min
- Washed 3 x 45 mL **saline + 1% autologous plasma** (250rcf)
- Stored overnight **4°C** saline + 20 autologous plasma
- Bone marrow aspirates diluted with 0.9% NaCl (1:5)
- Mononuclear cells isolated on **Ficoll™** gradient 800rcf 20 min
- Washed 3 x 45mL **PBS** (800rcf)
- Stored overnight **room temperature** in 10 + 20% autologous serum

Future Directions

- Standardization
 - Central cell processing facilities
 - Protocols
- Improved antimicrobial methods
 - Allergies
- Synthetic biology
 - Natural materials made synthetically, economically

Long-term: “clinical-grade” cell lines

- Animal-substance free conditions
 - Human feeder cells, chemically-defined media
 - Feeder-free culture
- No immune rejection, no immunosuppressive drugs
 - Somatic cell nuclear transfer
 - Genetic engineering, reprogramming
- Goals: understand normal/disease development, then repair/replace diseased organs and vice versa
 - Tissue engineering approach
 - ex vivo, in situ for now
 - In vitro for the future?

Summary

- Right combination of cell, scaffold, and factors depends on clinical problem
 - Extensive physician/scientist/engineering collaboration is vital to success
- Tissue engineering is leveraging our knowledge of cell biology and materials science to promote tissue regeneration where the natural process is not enough
 - Stem cells are an excellent tool for this task